# Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)

> **NCT01546532** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 118 (actual)

## Conditions studied

- Chronic Heart Failure (CHF)

## Interventions

- **DRUG:** RLX030
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01546532
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01546532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01546532, "Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01546532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*